Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Benjamin Rengstl"'
Autor:
John Haanen, Alexander Desuki, Andreas Mackensen, Ugur Sahin, Christian Koenecke, Winfried Alsdorf, Eva Wagner-Drouet, Daniel Heudobler, Peter Borchmann, Erol Wiegert, Catrine Schulz, Benjamin Rengstl, Liane Preussner, Oezlem Tuereci
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/03a34ed8c39847559a72de2bf4d73b7b
Autor:
Benjamin Rengstl, Sooji Kim, Claudia Döring, Christian Weiser, Julia Bein, Katrin Bankov, Marco Herling, Sebastian Newrzela, Martin-Leo Hansmann, Sylvia Hartmann
Publikováno v:
PLoS ONE, Vol 12, Iss 5, p e0177378 (2017)
The hallmark of classical Hodgkin lymphoma (cHL) is the presence of giant, mostly multinucleated Hodgkin-Reed-Sternberg (HRS) cells. Whereas it has recently been shown that giant HRS cells evolve from small Hodgkin cells by incomplete cytokinesis and
Externí odkaz:
https://doaj.org/article/4241835e3e834f84a9535c7a3a2c8d93
Autor:
Alexander H Benz, Christoph Renné, Erik Maronde, Marco Koch, Urszula Grabiec, Sonja Kallendrusch, Benjamin Rengstl, Sebastian Newrzela, Sylvia Hartmann, Martin-Leo Hansmann, Faramarz Dehghani
Publikováno v:
PLoS ONE, Vol 8, Iss 12, p e81675 (2013)
Cannabinoid receptor 1 (CB1) is expressed in certain types of malignancies. An analysis of CB1 expression and function in Hodgkin lymphoma (HL), one of the most frequent lymphomas, was not performed to date.We examined the distribution of CB1 protein
Externí odkaz:
https://doaj.org/article/75f4d2e90ae74646ae25c0d5991e3f8b
Autor:
Sylvia Hartmann, Claudia Döring, Christina Jakobus, Benjamin Rengstl, Sebastian Newrzela, Thomas Tousseyn, Xavier Sagaert, Maurilio Ponzoni, Fabio Facchetti, Chris de Wolf-Peeters, Christian Steidl, Randy Gascoyne, Ralf Küppers, Martin-Leo Hansmann
Publikováno v:
PLoS ONE, Vol 8, Iss 11, p e78812 (2013)
In contrast to the commonly indolent clinical behavior of nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), T cell/histiocyte rich large B cell lymphoma (THRLBCL) is frequently diagnosed in advanced clinical stages and has a poor prognosis. Be
Externí odkaz:
https://doaj.org/article/0f8283c1eacd47cca3c083f149f48a3d
Autor:
Matthias Birtel, Ralf-Holger Voss, Katharina Reinhard, Benjamin Rengstl, Yasmina Ouchan, Kristina Michel, Nina Hayduk, Bodo Tillmann, René Becker, Martin Suchan, Matthias Theobald, Petra Oehm, Özlem Türeci, Ugur Sahin
Publikováno v:
Cancer Research Communications. 2:827-841
Chimeric antigen receptor (CAR) T cells are efficacious in patients with B-cell malignancies, while their activity is limited in patients with solid tumors. We developed a novel heterodimeric TCR-like CAR (TCAR) designed to achieve optimal chain pair
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a6194315ef54821c15f36097b135ec10
https://doi.org/10.1158/2767-9764.crc-21-0154
https://doi.org/10.1158/2767-9764.crc-21-0154
Autor:
Ugur Sahin, Özlem Türeci, Petra Oehm, Matthias Theobald, Martin Suchan, René Becker, Bodo Tillmann, Nina Hayduk, Kristina Michel, Yasmina Ouchan, Benjamin Rengstl, Katharina Reinhard, Ralf-Holger Voss, Matthias Birtel
Supplementary Data and Figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::381bcc291c56fb9800786f04933391af
https://doi.org/10.1158/2767-9764.22545446
https://doi.org/10.1158/2767-9764.22545446
Autor:
Ugur Sahin, Özlem Türeci, Petra Oehm, Matthias Theobald, Martin Suchan, René Becker, Bodo Tillmann, Nina Hayduk, Kristina Michel, Yasmina Ouchan, Benjamin Rengstl, Katharina Reinhard, Ralf-Holger Voss, Matthias Birtel
Chimeric antigen receptor (CAR) T cells are efficacious in patients with B-cell malignancies, while their activity is limited in patients with solid tumors. We developed a novel heterodimeric TCR-like CAR (TCAR) designed to achieve optimal chain pair
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc213ba4971e2ef943dc981633019540
https://doi.org/10.1158/2767-9764.c.6550946.v1
https://doi.org/10.1158/2767-9764.c.6550946.v1
Autor:
Peter J. Madsen, Allison Stern, Crystal Griffin, Petr Oehm, Benjamin Rengstl, Carina Flemmig, Alexander Tucker, Phillip B. Storm, Adam C. Resnick, Jessica Foster
Publikováno v:
Neurosurgery. 69:57-57
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c8e26f8e9fc10d928785c7bc1dcd189d
https://doi.org/10.1227/neu.0000000000002375_351
https://doi.org/10.1227/neu.0000000000002375_351
Autor:
Daniel Heudobler, Oezlem Tuereci, Ugur Sahin, Erol Wiegert, John B. A. G. Haanen, Eva Wagner-Drouet, Catrine Schulz, Alexander Desuki, Andreas Mackensen, Winfried Alsdorf, Benjamin Rengstl, Peter Borchmann, Liane Preussner, Christian Koenecke
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundBNT211 is a chimeric antigen receptor (CAR)-T cell product candidate that targets the tumor specific antigen Claudin-6 (CLDN6). Preclinical studies demonstrated that combining these engineered cells with a CAR-T cell Amplifying RNA Vaccine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d3877de4fad47510e8c3d5704eb89bb
https://doaj.org/article/03a34ed8c39847559a72de2bf4d73b7b
https://doaj.org/article/03a34ed8c39847559a72de2bf4d73b7b
Autor:
Peter Madsen, Allison Stern, Crystal Griffin, Petra Oehm, Benjamin Rengstl, Carina Flemming, Adam C Resnick, Philip B Storm, Jessica Foster
Publikováno v:
Neuro-Oncology. 24:vii229-vii229
Atypical teratoid/rhabdoid tumor (ATRT) is an aggressive brain tumor that predominantly affects young children and has an average 5-year survival under 50%. Novel, targeted therapies are desperately needed. Claudin 6 (CLDN6) is a tight junction prote
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::534cf638629c1e33fe277ea7f7239eaf
https://doi.org/10.1093/neuonc/noac209.883
https://doi.org/10.1093/neuonc/noac209.883